Effect of Silymarin on Non Alcoholic Steatohepatitis
Phase 2
- Conditions
- on alcocholic steatohepatitis.Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT138805172308N1
- Lead Sponsor
- Mazandaran University of Medical Sciences and Health Services
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Including criteria: older than 20 years with nonalcoholic- fatty liver disease and liver enzymes> 50 and proportion of ALT/ AST> 1
Excluding criteria: using drugs that affect liver tests during the last 2 months, viral hepatitis, hemochromatosis, autoimmune hepatitis, cirrhosis, diabetes mellitus, alcohol dependency, pregnancy, breast feeding, and infectious diseases
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AST. Timepoint: Before and 6 months after the therapy. Method of measurement: laboratory.;ALT. Timepoint: Before and 6 months after the therapy. Method of measurement: laboratory.;Sonographic markers. Timepoint: Before and 6 months after the therapy. Method of measurement: by Radiologist.
- Secondary Outcome Measures
Name Time Method Weight. Timepoint: Before and 6 month after the therapy. Method of measurement: balance.;BMI. Timepoint: Before and 6 months after the therapy. Method of measurement: Weight(kg)/height^2(m2).;TG. Timepoint: Before and 6 months after the therapy. Method of measurement: laboratory.;FBS. Timepoint: before and 6 months after the therapy. Method of measurement: laboratory.